Flubromazolam

JYI-73, Liquid Xanax

Psychoactive Class

Depressant Sedative Anxiolytic Muscle Relaxant

Chemical Class

Flubromazolam is a novel synthetic depressant of the triazolobenzodiazepine class that produces anxiolytic, sedative, muscle relaxant, and amnestic effects. It is exceptionally potent, with activity in the microgram range, and possesses an unusually long duration of action. These properties pose heightened risks compared to other designer benzodiazepines, as strong sedation and amnesia can occur even at very low threshold doses. It has not been formally studied and is available exclusively through research chemical vendors.¹

Dosage & Duration

Dosage

Threshold~50 ug

Light100-150 ug

Moderate150-250 ug

Strong250-400 ug

Heavy400+ ug

This substance is exceptionally potent, and life-threatening adverse effects have been documented at doses as low as 3 mg.

Duration

Onset20-45 minutes

After Effects6-24 hours

Total12-18 hours

Subjective Effects

Effects vary widely by individual, dose, and context.

Physical

The physical effects of flubromazolam can be broken down into several components which progressively intensify proportional to dosage.

Motor control loss Respiratory depression Dizziness Muscle relaxation

Cognitive

The cognitive effects of flubromazolam can be broken down into several components which progressively intensify proportional to dosage. The general head space of flubromazolam is described by many as one of intense sedation and decreased inhibition. It contains a large number of typical depressant cognitive effects.

Amnesia Anxiety suppression Thought deceleration Disinhibition Information processing suppression Euphoria Compulsive redosing

Forked from Subjective Effect Documentation

by Josie KinsAugust 2015.

Reagent Testing

Loading reagent data

Expected colorimetric results are being prepared.

Pharmacology

Pharmacodynamics

Flubromazolam has not been extensively characterized in formal pharmacological studies, and its presumed mechanism of action is largely inferred from its structural classification as a triazolobenzodiazepine. Like other benzodiazepines, it is expected to act as a positive allosteric modulator at the benzodiazepine binding site of GABA-A receptors, enhancing the inhibitory signaling of gamma-aminobutyric acid (GABA) in the central nervous system.² The anticonvulsant properties observed with benzodiazepines may also involve binding to voltage-gated sodium channels. Flubromazolam is notably potent, with activity reported in the microgram range.

Pharmacokinetics

No specific pharmacokinetic data for flubromazolam, including metabolic pathways, enzyme involvement, or bioavailability, has been described in the available literature.

Metabolitesnone documented yet

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

AlcoholGHB/GBLOpioidsTramadol

Unsafe

Avoid

There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.

DiphenhydraminePCP

Caution

Use caution

These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.

DXMKetamineMXE

TripSit

Tolerance

Full Tolerance

Tolerance to sedative-hypnotic effects can emerge quickly, often after only a few days of uninterrupted use.

Cross Tolerance

Benzodiazepines (all)

Baseline Reset

Tolerance returns to baseline within 7-14 days after cessation of use. However, following prolonged or intensive use, this recovery period may be significantly extended in proportion to the duration and intensity of prior consumption.

Harm Potential

Addiction & Dependence

Psychological

High

Flubromazolam is described as extremely psychologically addictive. Compulsive redosing is commonly reported,³ and cycles of dependence can readily develop from rebound anxiety that follows the substance's effects wearing off.³

Physical

Extremely High

Physical dependence develops with regular use and can become life-threatening. Abrupt discontinuation after weeks of steady dosing can result in hypertension, seizures, and death.² Gradual tapering over a prolonged period is essential for safe discontinuation.

Toxicity

Respiratory

Respiratory depression occurs as a direct pharmacological effect with severity proportional to dose; this becomes potentially fatal when combined with other CNS depressants but rarely causes death from flubromazolam alone at typical doses.¹

Psychosis Risk

Paradoxical reactions including aggression, violent behavior, loss of impulse control, and irritability occur rarely, with an incidence rate below 1% in the general population.⁴ Delusions of sobriety commonly occur at heavy doses but represent cognitive impairment rather than true psychosis. Paradoxical effects are more frequent in recreational abusers, individuals with mental disorders, children, and those on high-dosage regimes.⁴

Seizure Risk

Benzodiazepines possess anticonvulsant properties during active use. Paradoxical seizure increases are rare and primarily affect individuals with epilepsy. However, withdrawal from regular use poses significant seizure risk that can be fatal;² drugs that lower seizure threshold should be avoided during discontinuation, and gradual tapering is essential.

History & Culture

Flubromazolam, also designated JYI-73, is a novel synthetic triazolobenzodiazepine that emerged as part of the broader wave of designer benzodiazepines appearing on recreational drug markets. The substance first came to the attention of drug monitoring agencies following seizures by customs and law…

Legality

By Country

United StatesSchedule I

Placed into Schedule I of the Controlled Substances Act as of January 23, 2023,⁶ indicating classification as having high abuse potential with no currently accepted medical use.

GermanyNpSG (Neue-psychoaktive-Stoffe-Gesetz)

Controlled under the New Psychoactive Substances Act since July 18, 2019. Production and import with intent to distribute, administration to another person, and trading are punishable offenses. Possession is technically illegal but not subject to criminal penalties.

PolandNPS controlled

Classified as a New Psychoactive Substance (NPS) under Polish drug legislation, making both possession and distribution illegal.

SwitzerlandVerzeichnis E

Specifically named as a controlled substance under Verzeichnis E of the Swiss Narcotics Act (Betäubungsmittelgesetz).

United KingdomClass C

Designated as a Class C controlled substance under the Misuse of Drugs Act 1971 as of May 31, 2017.⁵ Possession, production, and supply carry criminal penalties.

CanadaSchedule IV

All benzodiazepines are controlled under Schedule IV of the Controlled Drugs and Substances Act.

NetherlandsList 2 (Opiumwet)

Controlled under List 2 of the Opium Law (Opiumwet), making possession, distribution, and production illegal.

RussiaSchedule III

Listed as a Schedule III controlled substance since 2017 under Russian narcotics legislation.

TurkeyIllegal

Classified as a controlled drug under Turkish law. Possession, production, supply, and import are all prohibited.

References

Source Pages

Citations

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the Flubromazolam article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Flubromazolam

JYI-73, Liquid Xanax

Flubromazolam

Contents